menu
    • menu

    Company profile for Amunix

    Sanofi-PSE
    News
    Sanofi to divest cancer biotech it bought for $1B, axe 100 staffers in California

    11 Apr 2024

    // Ayisha Sharma ENDPTS

    Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors

    23 Jun 2021

    // GLOBENEWSWIRE

    Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR)

    13 Apr 2021

    // GLOBNEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    Sanofi

    Contact Supplier

    Website

    Biotech Digital Meet

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/fda-s-first-generic-approvals-slump-21-in-2024-novartis-top-seller-entresto-cancer-blockbuster-tasigna-lead-2024-patent-cliff

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Amunix is an immuno-oncology company leveraging our proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer. We aim to expand the therapeutic index of TCEs and cytokines, which have demonstrated anti-tumor clinical activity, but have not realized their potential due to dose-limiting on-target, off-tumor toxicity. We address this challenge by using our universal, protease-releasable masking technology (Pro-XTEN), to create next generation, conditionally active TCEs (XPATs®) and cytokines (XPACs)

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AmunixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Tower Pl #1100, South San Francisco, CA 94080 650-428-1800
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amunix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amunix/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi to divest cancer biotech it bought for $1B, axe 100 staffers in California
    Sanofi to divest cancer biotech it bought for $1B, axe 100 staffers in California

    11 Apr 2024

    // Ayisha Sharma ENDPTS

    https://endpts.com/sanofi-axes-100-staffers-in-california-home-to-amunix-which-it-bought-in-2021/

    Ayisha Sharma ENDPTS
    11 Apr 2024
    Share Share
    Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
    Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors

    23 Jun 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/06/23/2251610/0/en/Amunix-Appoints-Industry-Veteran-Frank-Watanabe-to-its-Board-of-Directors.html

    GLOBENEWSWIRE
    23 Jun 2021
    Share Share
    Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR)
    Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR)

    13 Apr 2021

    // GLOBNEWSWIRE

    https://www.globenewswire.com/news-release/2021/04/12/2208186/0/en/Amunix-Presents-Preclinical-Data-at-American-Academy-of-Cancer-Research-AACR-Annual-Meeting-from-Lead-Program-AMX-818-Demonstrating-Robust-Efficacy-in-HER2-Tumor-Models-and-Enhance.html

    GLOBNEWSWIRE
    13 Apr 2021
    Share Share
    Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline
    Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline

    04 Mar 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/03/04/2187044/0/en/Amunix-Raises-117-Million-Series-B-Financing-to-Fund-its-Oncology-Pipeline.html

    GLOBENEWSWIRE
    04 Mar 2021
    Share Share
    Amunix scores $117M to fuel T-cell engagers, cytokines
    Amunix scores $117M to fuel T-cell engagers, cytokines

    04 Mar 2021

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/amunix-scores-117m-to-fuel-t-cell-engagers-cytokines-for-solid-tumors#:~:text=Biotech-,Amunix%20scores%20%24117M%20to%20fuel%20T,engagers%2C%20cytokines%20for%20solid%20tumors&text=Exactly%20one%20year%20after%20Amunix,from%20the%20venture%20capital%20well.

    Amirah Al Idrus FIERCE BIOTECH
    04 Mar 2021
    Share Share
    ESMO: Amunix's T-cell engagers shrink solid tumors in animal models
    ESMO: Amunix's T-cell engagers shrink solid tumors in animal models

    17 Sep 2020

    // A. Weintraub FIERCE BIOTECH

    https://www.fiercebiotech.com/research/esmo-amunix-s-t-cell-engagers-shrink-solid-tumors-animal-models

    A. Weintraub FIERCE BIOTECH
    17 Sep 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search